Trials / Completed
CompletedNCT03526224
Teriflunomide Tecfidera LMCE
Effect of Teriflunomide on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective Observational Case-control Pilot Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (actual)
- Sponsor
- University at Buffalo · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the effect of teriflunomide in reducing cortical gray matter (CGM) atrophy and leptomeningeal (LM) inflammation over 24 months compared to dimethyl fumarate (Tecfidera®)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimethyl Fumarate | Individuals with MS treated with dimethyl fumarate (Tecfidera) |
| DRUG | Teriflunomide | Individuals with MS treated with teriflunomide (Aubagio) |
Timeline
- Start date
- 2018-06-14
- Primary completion
- 2019-07-10
- Completion
- 2019-07-10
- First posted
- 2018-05-16
- Last updated
- 2021-01-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03526224. Inclusion in this directory is not an endorsement.